Artigo · Revista · 2022

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial

Daniela Manno, Agnes Dora Bangura, Frank Baiden, Abu Bakarr Kamara, Philip Ayieko, Joseph Kallon e mais 24

The Lancet Infectious Diseases

• Acesso aberto · Híbrido
• Com uma empresa
• Internacional · 5 países

Lê-lo10.1016/s1473-3099(22)00594-1